Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma Review

  

Authors:	Korde, N.; Usmani, S. Z.
Review Title:	Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
Keywords:	treatment response; overall survival; lenalidomide; prednisone; thalidomide; drug tolerability; cancer combination chemotherapy; drug efficacy; follow up; progression free survival; bortezomib; multiple myeloma; maintenance therapy; dexamethasone; melphalan; transplantation; health care quality; add on therapy; minimal residual disease; autologous hematopoietic stem cell transplantation; carfilzomib; eligibility; transplant; clinical outcome; consolidation chemotherapy; human; article; ixazomib; newly diagnosed; daratumumab
Journal Title:	Hematology-Oncology and Stem Cell Therapy
Volume:	16
Issue:	2
ISSN:	1658-3876
Publisher:	Elsevier Inc.
Date Published:	2023-01-01
Start Page:	117
End Page:	123
Language:	English
DOI:	10.1016/j.hemonc.2021.07.001
PUBMED:	34343494
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112612324&doi=10.1016%2fj.hemonc.2021.07.001&partnerID=40&md5=08672caa079027e807586cb19b20428f
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/214779